{
  "docId": "019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "docSlug": "2cfade3d34acc49c8d5f05063b654956",
  "documentTitle": "ATAI | Investor Presentation Deck | 49 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 49,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a quote from Keith Nuechterlein and specific Cohen's d effect size metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-19a4-704e-b5bc-b8f4ae0c7550/20",
  "deckHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "deckJsonHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550.json",
  "deckAnchorHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.58,
        "x": 0.37,
        "y": 0.27
      },
      "kind": "chart",
      "text": "T-Scores (Normalized for age, gender, and education level) for HVLT, Symbol Coding, Category Fluency across 10mg, 20mg, 40mg, 80mg doses",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64e4da6d-4023-4bc6-a4b5-4a0535d51862",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.58,
        "x": 0.37,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "COMPLETED PHASE 2 PoM TRIAL: Single-arm, single-blind dose-ranging clinical trial timeline",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c293ef9-a26c-4d66-8bda-ae0050b20a22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.58,
        "x": 0.37,
        "y": 0.15
      },
      "kind": "quote",
      "text": "Symbol coding response is at a level that would correlate with better work/school performance",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "045b04d5-dacb-4036-a67d-614f27916380",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.58,
        "x": 0.37,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: CIAS = Cognitive impairment associated with schizophrenia; RL-007 is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salt; TID denotes 3x/day dosing",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42d1034a-2c48-4191-925d-6ddd73b9f69c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.34,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "table",
      "text": "OWNERSHIP 51.9% PRODUCT (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salt oral capsules (RL-007) PHARMACOLOGY Cholinergic, glutamatergic and GABA-B receptor modulator",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1c0fdc4-4b57-4705-ac0c-c0c3fe8d400d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.58,
        "x": 0.37,
        "y": 0.06
      },
      "kind": "title",
      "text": "RL-007 has previously shown pro-cognitive effects in human clinical studies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5947fd8d-a296-4d75-b434-22f6d991d04c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "8391b0e6-84c3-4256-8495-4ac18a0ea652",
      "evidence": "The slide provides a clear and concise summary of the product and its effects.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "cb5b07f4-73f0-4099-9303-43b01571fb1a",
      "evidence": "Clinical trial phase timeline shown at bottom",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}